Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Nuvance Health · NCT04406831

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
200
US sites recruiting
1
Study start
April 2015
Record last updated
April 13, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.

Being studied: Blood draw

Conditions: Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV; Pancreatic Ductal Adenocarcinoma; Pancreatic Neoplasms

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have biopsy proven adenocarcinoma of the pancreas
  • Have initially inoperable disease, classified as either locally advanced or metastatic disease
  • Recurrent disease after a Whipple procedure is allowed
  • Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
  • Have radiographically measurable disease
  • Have an ECOG performance status of 2 or less
  • Be willing to contribute the required information and specimens
  • Provide written signed consent to participate

Exclusion Criteria

  • Having received prior anti-cancer treatments for metastatic pancreatic cancer
  • Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
  • Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for >1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for > 5 years is allowable

Recruiting US locations

  • Nuvance Health

    Norwalk, CT 06856

    Site contact: Tammy Lo, APRN · 203-855-3551 · Tammy.Lo@nuvancehealth.org

Study contacts (from the official record)

  • Pramila Krumholtz, RN · pramila.krumholtz@nuvancehealth.org
  • Tammy Lo, MSN · tammy.lo@nuvancehealth.org
All healthy volunteers studies in Connecticut →
The Role of MicroRNA in the Diagnosis, Prognosis and Response to… (NCT04406831) | Bored Studies